JAGOTEC AG Patent applications |
Patent application number | Title | Published |
20140314684 | MEDICINAL AEROSOL FORMULATIONS - The present invention provides a process for making a stabilized medical aerosol suspension formulation for administration by a pressurized metered dose inhaler. | 10-23-2014 |
20140243296 | Organic Compounds - A treatment regimen and dosage form comprising ritonavir and darunavir and their use in the treatment of HIV infection. | 08-28-2014 |
20140150788 | Dry Powder For Inhalation - The present invention provides dry powder formulations for inhalation having improved moisture resistance such that the powders maintain a high fine particle dosage or fine particle fraction following storage under relatively extreme temperature and humidity conditions. | 06-05-2014 |
20130122061 | Delayed Release Tablet With Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 05-16-2013 |
20130108695 | Dosage Form | 05-02-2013 |
20130079415 | COMPOSITIONS COMPRISING AMPHETAMIN AND LISDEXAMFETAMINE - A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue. | 03-28-2013 |
20130014758 | DRY POWDER FORMULATIONS - A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes. | 01-17-2013 |
20120328704 | POWDER COMPOSITIONS FOR INHALATION - The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C. | 12-27-2012 |
20120282189 | Improved Medicinal Aerosol Formulations - The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronised pa-agonist; b) micronised corticosteroid; c) a siib-therapexrtic quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant. | 11-08-2012 |
20120213910 | Tablets with Site- and Time- Controlled Gastrointestinal Release of Active Ingredient - The present invention describes a pharmaceutical dosage form with site- and time-controlled gastrointestinal release of active ingredient. | 08-23-2012 |
20120196938 | Beta 2 Adrenergic Receptor Agonists Such As Terbutaline for Use in the Treatment of Nocturnal Hypoglycemia - The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening. | 08-02-2012 |
20120177739 | Delayed Release Tablet with Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 07-12-2012 |
20120177734 | Delayed Release Tablet with Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 07-12-2012 |
20120107406 | Dry Powder Formulations - A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes. | 05-03-2012 |
20120064160 | Fibrate-statin Combinations with Reduced Fed-fasted Effects - This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal. | 03-15-2012 |
20110244032 | DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES - Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less. | 10-06-2011 |
20110177167 | Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet. | 07-21-2011 |
20110114092 | Dry Powder for Inhalation - The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. On of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions. | 05-19-2011 |
20100065048 | DRY POWDER INHALER DEVICES - A DPI device comprising a dispensing chamber for receiving a discrete dose of medicament-containing powder and means for delivering said dose from the dispensing chamber to a patient in an air-flow that passes from the chamber to the patient via a mouth-piece along a first air passage that comprises de-agglomerating means, the device additionally comprises a second air passage in fluid communication with the dispensing chamber and the mouth-piece and which by-passes the de-agglomerating means and which is located such that it receives a portion of said air-flow that is free, or substantially free, of powder. | 03-18-2010 |
20100015238 | Powder Compositions for Inhalation - A pharmacological powder for inhalation comprising fine particles of a drug and particles of a force-controlling agent, wherein the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The powder may further comprise particles of a carrier material for supporting the drug particles. The force-controlling agent may be selected from: amino acids, peptides and polypeptides having a molecular weight of from 0.25 to 1000 KDa; phospholipids; titanium dioxide; aluminium dioxide; silicon dioxide; starch; and salts of fatty acids. Also disclosed is a method of making such a powder for inhalation comprising mixing a force-controlling agent with particles of one or more pharmacologically active materials to obtain a mixture in which the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The mixing step may be achieved by sieving, mixing or blending, micronising and/or co-micronising the particles of one or more pharmacologically active material and particles of force-controlling agents. | 01-21-2010 |
20100003320 | HYDROPHILIC/LIPOPHILIC POLYMERIC MATRIX DOSAGE FORMULATION - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet. | 01-07-2010 |